Biotech Values

[jbog]

While that could work out it's potentially a nightmare scenario. Much rather see an appropriate partnership.

If Partnering was on the horizon I wouldn't have thought they'd do this raise. Their initial payment from a partner would be high considering most of the risk has been covered at this point. It's rare when a pharma partners after the ph 3's have shown superiority.